Literature DB >> 3587919

Multivariate analysis of risk factors for metastasis in retinoblastoma treated by enucleation.

J E Kopelman, I W McLean, S H Rosenberg.   

Abstract

Retinoblastoma, when it kills by metastasis, almost always does so within 5 years of enucleation. The median time to death was 6.4 months in unilateral cases and 14.2 months in bilateral cases. Multivariate statistical analysis of 361 cases of retinoblastoma indicated that histologic detection of invasion of the tumor into the optic nerve or orbit were the risk factors most highly predictive of death from retinoblastoma. Choroidal invasion was not significantly associated with a fatal outcome. Histologic evidence of a cataract, failure to diagnose retinoblastoma clinically, and bilaterality were also significant risk factors. The authors believe that in at least two of the cases of bilateral retinoblastoma death did not result from metastasis to the brain as was originally diagnosed, but resulted from the development of an independent primary intracranial neuroblastic tumor, a syndrome designated "trilateral retinoblastoma."

Entities:  

Mesh:

Year:  1987        PMID: 3587919     DOI: 10.1016/s0161-6420(87)33436-0

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  29 in total

1.  Retinoblastoma - MR appearance using a surface coil in comparison with histopathological results.

Authors:  Arne-Jörn Lemke; Iris Kazi; Ulrike Mergner; Paul Ivan Foerster; Heinrich Heimann; Nikolaos Bechrakis; Andreas Schüler; Marie-Isabell Senfft von Pilsach; Michael Foerster; Roland Felix; Norbert Hosten
Journal:  Eur Radiol       Date:  2006-04-25       Impact factor: 5.315

Review 2.  Chemotherapy for retinoblastoma: a current topic.

Authors:  P T Finger; G Czechonska; H Demirci; A Rausen
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

3.  Retinoblastoma. Fifty years of progress. The LXXI Edward Jackson Memorial Lecture.

Authors:  Hans E Grossniklaus
Journal:  Am J Ophthalmol       Date:  2014-07-24       Impact factor: 5.258

4.  Enucleation vs Ophthalmic Artery Chemosurgery for Advanced Intraocular Retinoblastoma: A Retrospective Analysis.

Authors:  Nicolas Alessandro Yannuzzi; Jasmine H Francis; Brian P Marr; Irina Belinsky; Ira J Dunkel; Yves Pierre Gobin; David Harold Abramson
Journal:  JAMA Ophthalmol       Date:  2015-09       Impact factor: 7.389

5.  Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy: A Children's Oncology Group Study.

Authors:  Patricia Chévez-Barrios; Ralph C Eagle; Mark Krailo; Jin Piao; Daniel M Albert; Yun Gao; Geeta Vemuganti; Mohammad Javed Ali; Vikas Khetan; Santosh G Honavar; Joan O'Brien; Ann-Marie Leahey; Katherine Matthay; Anna Meadows; Murali Chintagumpala
Journal:  J Clin Oncol       Date:  2019-09-20       Impact factor: 44.544

6.  High-risk histomorphological features in retinoblastoma and their association with p53 expression: An Indian experience.

Authors:  Rao Seema; Sobti Parul; Khurana Nita
Journal:  Indian J Ophthalmol       Date:  2014-11       Impact factor: 1.848

7.  Diagnostic performance of MRI of post-laminar optic nerve invasion detection in retinoblastoma: A systematic review and meta-analysis.

Authors:  Se Jin Cho; Jae Hyoung Kim; Sung Hyun Baik; Leonard Sunwoo; Yun Jung Bae; Byung Se Choi
Journal:  Neuroradiology       Date:  2020-08-31       Impact factor: 2.804

8.  [Morphologic classification of choroidal invasion of retinoblastoma].

Authors:  H Yang; H Schilling; R Effert; A Wessing
Journal:  J Tongji Med Univ       Date:  1999

9.  Choroidal invasion of retinoblastoma: metastatic potential and clinical risk factors.

Authors:  C L Shields; J A Shields; K A Baez; J Cater; P V De Potter
Journal:  Br J Ophthalmol       Date:  1993-09       Impact factor: 4.638

10.  Tumour angiogenesis as a prognostic factor for disease dissemination in retinoblastoma.

Authors:  E Ferrari Marback; V E A Arias; A Paranhos; F A Soares; A L Murphree; C M Erwenne
Journal:  Br J Ophthalmol       Date:  2003-10       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.